Author

A. Pinto

Observed name: A. A. Pinto

Institution: Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Observed institution: Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

OpenAlex ID: A5029744656

S173: T-cell Activation and Myeloma Cell Killing Confirm the Mode of Action of Rg6234, a Novel Gprc5d T-cell Engaging Bispecific Antibody, in Patients With Relapsed/refractory Multiple Myeloma

2022 · I. Dekhtiarenko, I. Lelios, et al. · HemaSphere · 1

Phase 1 trial of EO2463 peptide‐based immunotherapy as monotherapy and in combination with lenalidomide and rituximab in indolent non‐Hodgkin lymphoma; EONHL1‐20/SIDNEY

2023 · A. A. Pinto, F. Bosch, et al. · Hematological Oncology

P1115: a Multicenter Phase 1/2 Trial of Eo2463, a Microbial-derived Peptide Therapeutic Vaccine, as Monotherapy and in Combination With Lenalidomide and Rituximab, for Treatment of Patients With Indolent Nhl

2022 · P. L. Zinzani, S. M. Ansell, et al. · HemaSphere

Works count: 3

Citation count: 1

H-index: 1

I10-index: